A Study of prediction of onset and course of interstitial pneumonitis for treated advanced renal cell carcinoma with mTOR inhibitor(everolimus or temsirolimus) by measurement of fraction of exhaled nitric oxide

A Study of prediction of onset and course of interstitial pneumonitis for treated advanced renal cell carcinoma with mTOR inhibitor(everolimus or temsirolimus) by measurement of fraction of exhaled nitric oxide - A Study of prediction of onset and course of interstitial pneumonitis by measurement of fraction of exhaled nitric oxide

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007081

Enrollment

Registered

2012-01-17

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inoperable or metastatic renal cell carcinoma treated with mTOR inhibitor (everolimus or temsirolimus)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)written informed consent 2)patients performed pulmonary function tests

Exclusion criteria

Exclusion criteria: 1)not written informed consent 2)patients with pulmonary function testing can not be done 3)bronchial asthma patients 4)smoker

Design outcomes

Primary

Measure	Time frame
Correlation between exhaled NO and interstial pneumonia in the course of mTOR inhibitor therapy	—

Countries

Japan

Contacts

Public ContactKazumi Nishino

Osaka medical center for cancer and cardiovascular diseases Pulmonary oncology

nisino-ka@mc.pref.osaka.jp06-6972-1181

Outcome results